Atezolizumab Plus Vemurafenib/Cobimetinib Produces Intracranial Activity in BRAF V600–Mutant Melanoma With CNS Metastases
Source: Onc Live, August 2022
The addition of atezolizumab (Tecentriq) to vemurafenib (Zelboraf) and cobimetinib (Cotellic) produced promising intracranial activity in patients with BRAF V600–mutated advanced melanoma and central nervous system (CNS) metastases, according to data from the phase 2 TRICOTEL trial (NCT03625141) published in The Lancet.
At a median follow-up of 9.7 months (interquartile range [IQR], 6.3-15.0), patients in the BRAF V600 mutation–positive cohort (n = 65) achieved an intracranial objective response rate (ORR) of 42% (95% CI, 29%-54%) per independent review committee (IRC) assessment. Of these responders, 6% experienced a complete response (CR), 35% had a partial response (PR), 28% had stable disease, 5% had a non-CR or progressive disease, 20% experienced progressive disease, 2% were not evaluable, and 5% were missing. The disease control rate at 16 weeks was 38% (95% CI, 27%-61%), and the median intracranial duration of response (DOR) was 7.4 months (95% CI, 5.7-11.0).
At a median follow-up of 6.2 months (IQR, 3.5-23.0), patients in the BRAF V600 wild-type cohort (n = 15) who were treated with atezolizumab plus cobimetinib experienced an intracranial ORR of 27% (95% CI, 8%-55%) per investigator assessment.